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Background. Although antiretroviral therapy improves immune response, some human immunodeficiency
virus–infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in
increased morbidity and mortality.
Methods. Cross-sectional, case-control study to characterize the mechanism and to identify predictive factors
of poor immune response. We included 230 patients who were receiving highly active antiretroviral therapy and
who had a viral load !50 copies/mL for 12 years; 95 were “discordant” (case patients; CD4 T cell count always
!350 cells/mL), and 135 were “concordant” (control subjects). Activation markers, CD4 T cell death (necrosis,
intrinsic apoptosis, and extrinsic apoptosis), and caspase-3 were measured. Clinical parameters, particularly an-
tiretroviral combinations, were correlated with immune recovery.
Results. Discordant patients showed higher levels of activation markers, mainly in CD4 T cells ( ), andP ! .001
higher rates of spontaneous cell death ( ). Rates of activation and rates of CD4 T cell death (mainly byP ! .001
intrinsic apoptosis) were the best predictive factors for immune recovery, along with nadir CD4 T cell count.
Patients who were receiving a protease inhibitor–based regimen were more likely to be discordant and showed
higher rates of activation ( ), higher rates of CD4 T cell death ( ), and a lower nadir CD4 T cellPp .011 Pp .033
count ( ). Multivariate analysis, however, ruled out any effect of protease inhibitors on immune recovery.P ! .001
No differences were observed between the use of tenofovir-emtricitabine (Truvada) and the use of abacavir-
lamivudine (Kivexa).
Conclusions. CD4 T cell apoptosis by the intrinsic pathway represents the determinant mechanism of the
unsatisfactory immune recovery and should be targeted to manage therapy for discordant patients. The predictive
value of low nadir CD4 T cell count for a poor immune recovery led us to consider starting antiretroviral therapy
earlier. No differences were observed among antiretrovirals in terms of immune recovery.
Clinicians who care for individuals infected with hu-
man immunodeficiency virus (HIV) are concerned about
the lack of immune recovery in some virologically sup-
pressed patients. This group, called discordant or im-
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munological nonresponder patients, is defined as pa-
tients who are receiving highly active antiretroviral ther-
apy (HAART) and who maintain suppression of HIV
replication without an adequate CD4 T cell count re-
covery. Unlike full responders, discordant patients are
at increased risk of clinical progression to AIDS-related
and non–AIDS-related illnesses and death [1–7]. Co-
hort studies reveal a substantial prevalence of immu-
nological nonresponders among patients who are re-
ceiving HAART, ranging from 17% to 40%, depending
on the study criteria and the population [5, 8, 9]. These
data indicate that a high number of treated HIV-in-
fected patients are at risk of clinical progression.
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From a clinical point of view, older age [10, 11], lower nadir
CD4 T cell count [1, 10, 12], and hepatitis C virus (HCV)
coinfection [13–15] are some of the most relevant predictive
factors for a discordant response. Critical questions, such as
the choice of the most appropriate antiretroviral therapy in
these cases, remain unanswered.
There has been a great deal of effort aimed at understanding
the virological and immunological basis for poor immune re-
covery. In general, low production of new T cells, due to im-
paired bone marrow or thymus function [1, 16–18], and in-
creased CD4 T cell destruction, revealed by the high sensitivity
to cell death ex vivo [17, 18], have been shown to contribute
to this failure. Also, the unbalanced T cell homeostasis may
be influenced by the existence of latent, undetectable, ongo-
ing viral replication [19], microbial translocation from the gas-
trointestinal lumen [20], and adverse effects of antiretroviral
drugs at the mitochondrial level [21]. Each of these conditions
can influence the production, activation, and death of CD4
T cells and thus determine the discordant response.
In this regard, we have recently observed that an increased
rate of CD4 T cell death appears to be a determining factor
for poor immune recovery in a group of 95 immune-discordant
patients, compared with 135 responders (Massanella et al, un-
published data). Such increased destruction of CD4 T cells is
closely related to immune hyperactivation, because activated
cells are prone to apoptosis ex vivo [22]. However, the ultimate
cause of the unfavorable immune response has not been iden-
tified. A better knowledge of the definitive pathogenic mech-
anism and the factors influencing CD4 T cell recovery would
help investigators to design adequate strategies focused on im-
proving the immunological response in discordant patients and
to determine the optimal therapeutic approach for them.
The present study was designed on the basis of the hypotheses
that CD4 T cell apoptosis determines the immune recovery
after HAART and that some clinical conditions, such as coin-
fection or a specific antiretroviral treatment, are triggering fac-
tors for discordant response. Accordingly, the aims of this study
were to identify the CD4 T cell death pathways that limit re-
covery of CD4 T cells and to determine their association with
clinical parameters and antiretroviral regimens.
MATERIALS AND METHODS
Study design and population. We performed a cross-sec-
tional, case-control study to analyze the role of cell death in
discordant immune response. A 12-month period of inclusion
(1 November 2007–31 October 2008) was chosen, with the
assumption that during this period all discordant patients in
our cohort could be identified. We screened 247 consecutive
patients who attended our HIV Outpatient Unit, and 230 met
the following inclusion criteria: (1) confirmed diagnosis of HIV
infection, (2) continual HAART for 12 years that included 2
nucleoside reverse-transcriptase inhibitors (NRTIs) plus 1 ri-
tonavir-boosted protease inhibitor (PI) or 1 nonnucleoside re-
verse-transcriptase inhibitor (NNRTI) (nevirapine or efavi-
renz), and (3) sustained undetectable levels of HIV-1 RNA
(plasma viral load, !50 copies/mL) for 12 years (minimum
number of determinations, 4). The exclusion criteria were
chemotherapy, treatment with interferon and/or ribavirin, a
history of opportunistic infection during the previous 2 years,
and the presence of decompensated liver cirrhosis.
We considered to be discordant (ie, having favorable viro-
logical but unfavorable immunological response) those patients
with a CD4 T cell count that was always !350 cells/mL. Con-
versely, concordant patients (favorable virological and immu-
nological response) showed a current CD4 T cell count 1400
cells/mL. These criteria ensured that patients with a CD4 T cell
count from 350 to 400 cells/mL were excluded from the study,
to clearly distinguish the 2 immune scenarios (discordant and
concordant response).
The Institutional Review Board of our center approved the
study (EO code: EO-07–024). All patients provided their writ-
ten informed consent.
Study objectives and end points. The main objective of the
study was to characterize the cell death pathways that lead to
a poor CD4 T cell recovery. Our main end points were the
rates of total cell death, necrosis, and apoptosis (intrinsic and
extrinsic), compared between discordant and concordant pa-
tients. Another objective was the comparison of the levels of
CD4 T cell activation and of caspase-3 between discordant and
concordant patients. Finally, we investigated the influence of
clinical parameters on immune recovery, particularly the effect
of different antiretroviral combinations, according to whether
they included a PI, an NNRTI, or the most frequently used
coformulated NRTIs tenofovir-emtricitabine (Truvada) or abaca-
vir-lamivudine (Kivexa).
Assessments. Information on patient characteristics and
HIV-related data was collected from medical records. The
status of infection with hepatitis B virus (HBV) or with HCV
was also retrieved from this patient history database.
A single blood sample was drawn from each participant.
Blood was immediately stained and processed. Plasma was ob-
tained by centrifugation of blood at 1200 g for 10 minutes and
was stored at !80"C. Peripheral blood mononuclear cells
(PBMCs) were obtained from cell concentrates layered on Fi-
coll–Hypaque density gradients (Atom Reactiva) and were used
immediately for ex vivo cell death assays or were frozen for
caspase-3 determinations.
Cell death was evaluated by culturing aliquots of 200,000
PBMCs in 96-well plates in 100 mL of Roswell Park Memorial
Institute medium (containing 10% fetal calf serum) for 0, 1,
and 4 days in the absence or presence of the pancaspase in-
hibitor Z-VAD-fmk (R & D Systems). Cells were analyzed in
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an LSRII flow cytometer (Becton Dickinson) after incubation
with 40 nM of the potentiometric mitochondrial probe DiOC6
(Invitrogen), 5 mg/mL propidium iodide (Sigma), and CD3-
APC-Cy7, CD4-APC, and CD8-PE-Cy7 antibodies. Total cell
death was calculated as the percentage of cells that showed low
DiOC6 staining in control cultures [23].
On day 1, we performed additional analyses of necrotic cell
death (caspase-independent), which was defined as the per-
centage of propidium iodide–stained cells in cultures that con-
tained Z-VAD-fmk. Apoptotic cell death was defined as caspase-
dependent death and was calculated by subtracting necrosis
from total cell death. Intrinsic apoptosis was defined as the
percentage of cells that showed low DiOC6 staining and that
remained negative for propidium iodide in the presence of Z-
VAD-fmk. Extrinsic apoptosis was calculated as the difference
between total and intrinsic apoptosis. Caspase-3 activity was
determined using 15 mg of total protein from PBMC lysates
with a fluorometric assay (Ac-DEVD-AMC, CASPASE-3; Bec-
ton Dickinson).
CD4 and CD8 T cell immunophenotypes were assessed by
staining fresh blood samples with the following antibody com-
bination: CD95-FITC, PD-1-PE, HLA-DR-PerCP, CD3-APC-
Cy7, CD4-APC, and CD8-PE-Cy7, which was designed to eval-
uate activation. A control staining and a control combination
that contained CD3-APC-Cy7, CD4-APC, and CD8-PE-Cy7
antibodies were performed for all samples. Cells were acquired
in the LSRII flow cytometer and were analyzed with FlowJo
software (Tree Star).
Soluble CD14 levels, which are a surrogate marker for bac-
terial translocation [24], were quantified in all plasma samples
by means of commercially available enzyme-linked immuno-
sorbent assays (Diaclone). Plasma samples were diluted (1:50)
and were tested in duplicate.
Statistical analysis. Continuous variables were expressed
as the median (interquartile range [IQR]) and were compared
using nonparametric tests (Mann-Whitney for nonpaired data
and Wilcoxon for paired data), because the parameters were
not normally distributed. Discrete variables were described as
number of patients (percentage), and the x2 or Fisher exact test
was used, as appropriate. The Pearson correlation coefficient
was calculated to assess the association between the apoptosis
parameters and the clinical variables.
Univariate and multivariate logistic regressions were fitted
to predict the probability of discordance by considering the
following as explanatory variables: age, sex, route of transmis-
sion, time with HIV infection, time receiving antiretroviral ther-
apy, antiretroviral used at baseline, time with suppressed viral
load, nadir CD4 T cell count, baseline CD4 T cell count, coin-
fection with HBV or HCV, and hepatitis C viral load. The
models were also fitted after adjustment for use of PI and for
HCV coinfection.
Statistical analyses were performed using SPSS, version 15.0
(SPSS), with univariate 2-tailed significance levels of .05. Graphs
were plotted with GraphPad Prism, version 5 (GraphPad).
RESULTS
Patient characteristics. A total of 230 patients were included
in the study: 95 were defined as discordant and 135 as con-
cordant. Most demographic and clinical parameters were well
balanced among both groups (Table 1). However, minimal but
significant differences were observed in the time with viral load
!50 copies/mL and in CD8 T cell absolute counts. As expected,
significantly lower CD4 T cell counts (absolute and percentage),
significantly lower nadir CD4 T cell counts, and a significantly
higher number of patients with nadir CD4 T cell counts !200
cells/mL were observed in the discordant group ( forP ! .001
all). Patients with HCV coinfection and patients who were
receiving PI-containing regimens were more likely to be found
in the discordant group (Table 1).
Analysis of activation and destruction and characterization
of cell death pathways. Cell death was measured in CD4 and
CD8 T cells immediately after cell purification (day 0) and after
1 or 4 days of ex vivo culture. In particular, levels of an activation
marker (CD4+HLA-DR+CD95+) and rates of total death in CD4
T cells were significantly higher in discordant patients (P !
) (Table 1 and Figure 1A). Conversely, although CD8 T cells.001
showed increased levels of activation markers (CD8+HLA-
DR+CD95+) (Table 1), no significant differences in rates of ex
vivo cell death were observed in this subset (Figure 1A).
With regard to the mechanisms of cell death, the discordant
group showed higher rates of necrosis and of total apoptosis
(intrinsic and extrinsic) in CD4 T cells at day 1, compared with
the corresponding rates for concordant patients (Figure 1B).
In contrast, CD8 T cells from discordant patients showed higher
rates of necrosis and intrinsic apoptosis but lower rates of ex-
trinsic apoptosis (Figure 1C). Levels of caspase-3 were signif-
icantly higher in discordant patients (10,409 absorbance units/
mg protein [IQR, 7018–16,203 absorbance units/mg protein])
than in concordant patients (9035 absorbance units/mg protein
[IQR, 5080–13,358 absorbance units/mg protein]) ( ).Pp .050
Rates of CD4 T cell intrinsic apoptosis showed a stronger
correlation than did rates of necrosis or extrinsic apoptosis
with the expression of different markers of activation, such
as the frequency of CD38+CD45RA! CD4 T cells (r, 0.617;
) and HLA-DR+CD95+ CD4 T cells (r, 0.523; ).P ! .001 P ! .001
This finding suggests that activated cells die mainly by intrinsic
apoptosis.
Clinical parameters that influenced cell death and discor-
dant response. On inclusion, 55% of participants were re-
ceiving a stable PI-based regimen, mainly atazanavir (44.3%)
and lopinavir-ritonavir (44.3%), and 45% were receiving an
NNRTI-based regimen. Patients who were receiving a PI-con-
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Table 1. HIV-Related Characteristics and Activation Markers for Concordant and Discordant Patients
Variable
Concordant patients
(n p 135)
Discordant patients
(n p 95) P
Age, years 43 (39–50) 46 (42–50) .061
Male sex, no. (%) of patients 100 (74) 78 (82) .200
Time since HIV diagnosis, months 155 (108–197) 170 (88–242) .310
Time receiving ART, months 131 (95–161) 114.5 (55–169) .165
Time with VL !50 copies/mL, months 49 (31–73) 40 (27–60) .030
Nadir CD4 T cell count, cells/mL 234 (132–319) 71 (28–135) !.001
Nadir CD4 T cell count !200 cells/mL, no. (%) of patients 61 (45) 85 (90) !.001
Absolute CD4 T cell count, cells/mL 632 (480–796) 249 (200–319) !.001
CD4 T cell count, % 30 (26–36) 18 (14–21) !.001
Time to achieve current CD4 T cell count, monthsa 131 (95–157) 113 (55–169) .200
Absolute CD8 T cell count, cells/mL 805 (648–1112) 724 (510–986) !.001
CD8 T cell count, % 51 (45–58) 41 (35–48) .023
Current ART, no. (%) of patients
PI 50 (37) 53 (55) .007
NNRTI 84 (63) 43 (45) .015
TDF-FTC (Truvada) 68 (50) 47 (49) .187
ABV-3TC (Kivexa) 28 (21) 23 (24) .165
HCV coinfection, no. (%) of patients 43 (32) 44 (46) .028
HBV coinfection, no. (%) of patients 6 (4) 4 (4) 1.99
CD8+HLA-DR+CD95+, % of CD8 T cells 8.2 (4.3–11.6) 12.4 (6.2–19.6) !.001
CD4+HLA-DR+CD95+, % of CD4 T cells 4.7 (3.2–6.9) 10.1 (6.7–19.2) !.001
NOTE. Data are median (interquartile range), unless otherwise indicated. All participants had a human immunodeficiency viral load !50 copies/
mL for 12 years. Discordant patients were defined by a CD4 T cell count always !350 cells/mL. Concordant patients were defined by a CD4 T
cell count always 1400 cells/mL. ABV, abacavir; ART, antiretroviral treatment; FTC, emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus;
HIV, human immunodeficiency virus; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir; VL, viral load;
3TC, lamivudine.
a Time from starting antiretroviral to current CD4 T cell count.
taining regimen were mostly in the discordant group (Table 1)
and showed a lower nadir CD4 T cell count, a higher propor-
tion of patients with nadir CD4 T cell count !200 cells/mL, a
longer period with HIV infection, a shorter time with viral
suppression, and more common HCV coinfection (Table 2).
Significant differences were also seen in levels of activation
markers (CD8+CD38+CD45RA!, ), rates of CD4 T cellPp .011
death ( ), levels of soluble CD14 ( ), and ratesPp .033 Pp .002
of total ( ), intrinsic ( ), and extrinsic (Pp .041 Pp .038 Pp
) apoptosis (Table 2). CD8 T cells showed similar char-.033
acteristics in both groups (data not shown).
No differences were observed between patients who were
receiving tenofovir-emtricitabine and patients who were re-
ceiving abacavir-lamivudine with regard to immune recovery,
T cell production, activation, or destruction (data not shown).
Compared with patients without HCV coinfection, patients
with HCV coinfection were more likely to be discordant (Ta-
ble 1) and presented a lower nadir CD4 T cell count (Pp
), longer time with HIV infection ( ), and high-.021 Pp .017
er levels of immune markers (HLA-DR+CD95+ CD4 T-cells,
; and CD38+CD45RA! CD8 T-cells, ) and ofPp .003 Pp .017
soluble CD14 ( ). CD4 T cell destruction and productionP ! .001
were similar between patients with and patients without HCV
coinfection.
Univariate and multivariate analyses. In the univariate
analysis (Figure 2A), there were statistically significant associ-
ations between poor immune recovery and low nadir CD4 T
cell count, HCV coinfection, and PI use. The rate of death in
the CD8 T cell subset was unrelated to or poorly predictive of
the discordant phenotype. However, the same parameters mea-
sured in CD4 T cells were statistically significant. Of note, the
rate of CD4 T cell death at day 0 and the rates of necrosis and
intrinsic apoptosis at day 1 were the best predictors of discor-
dance. No association was seen with age, sex, time with HIV
infection, time with viral suppression, or type of NNRTI used.
In the multivariate analysis (Figure 2B), discordance was
more likely in patients who presented a low nadir CD4 T cell
count (odds ratio [OR], 1.739; 95% confidence interval [CI],
1.351–2.129; ), high rates of necrosis in CD4 T cellsP ! .001
(OR, 1.515; 95% CI, 1.053–2.180; ), and high rates ofPp .025
CD4 T cell intrinsic apoptosis at day 1 (OR, 2.266; 95% CI,
1.455–3.531; ).P ! .001
These increased risks changed slightly after adjustment for
PI use: low CD4 nadir T cell counts (OR, 1.653; 95% CI, 1.351–
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Figure 1. Analysis of cell death mechanisms. Total cell death in CD4 T cells and CD8 T cells was evaluated after 0, 1, and 4 days ex vivo cultures
of peripheral blood mononuclear cells (PBMCs) (panel A). Different mechanisms of cell death (necrosis, total apoptosis, intrinsic apoptosis, and extrinsic
apoptosis) in CD4 T cells (panel B) and in CD8 T cells (panel C) were analyzed after 1 day ex vivo cultures of PBMCs. Individual measures of concordant
patients (green symbols) or discordant patients (red symbols) with the median values (black lines) and interquartile ranges (black bars) are shown. P
values were calculated with the Mann-Whitney test.
2.129; ), high rates of necrosis of CD4 T cells at day 1P ! .001
(OR, 1.523; 95% CI, 1.057–2.194; ), and high rates ofPp .024
CD4 T cell intrinsic apoptosis (OR, 2.277; 95% CI, 1.458–3.555;
). Because the criterion for the identification of dis-P ! .001
cordant patients was based on absolute CD4 T cell counts, we
investigated the role of intrinsic apoptosis in CD4 T cell re-
covery after stratification of all patients ( ) accordingnp 230
to their increase in CD4 T cells (difference between their cur-
rent and nadir CD4 T cell counts). Higher increases in CD4 T
cells were associated with lower intrinsic apoptosis ( )P ! .001
(Figure 2C).
DISCUSSION
A decreased thymic production and an increased activation and
death of CD4 T cells are some of the proposed mechanisms to
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Table 2. Characteristics of HIV-Infected Patients according to Regimen Based on Protease Inhibitor (PI) or Nonnucleoside
Reverse-Transcriptase Inhibitor (NNRTI)
Characteristic
PI-based regimen
(n p 103)
NNRTI-based regimen
(n p 127) P
Age, years 44 (41–48) 45 (40–51) .613
Male sex, no. (%) of patients 78 (76) 100 (79) .636
Time since HIV diagnosis, months 175 (123–230) 143 (27–206) .017
Time with VL !50 copies/mL, months 38 (23–63) 51 (34–74) .001
Nadir CD4 T cell count, cells/mL 92 (39–185) 189 (91–304) !.001
Nadir CD4 T cell count !200 cells/mL, no. (%) of patients 80 (78) 66 (52) !.001
HCV coinfection, no. (%) of patients 55 (53) 32 (25) !.001
Discordant, no. (%) of patients 58 (56) 47 (37) .007
CD4+CD45RA+CD31+, % of CD4 T cells 17.4 (8.5–27.5) 15.6 (7.4–22.8) .148
CD4+HLA-DR+CD95+, % of CD4 T cells 7.0 (3.9–12.6) 6.1 (4.2–8.9) .225
CD8+CD38+CD45RA!, % of CD8 T cells 28.0 (18.7–39.3) 22.9 (16.8–31.4) .011
Soluble CD14, mg/mL 8.9 (7.7–10.5) 8.0 (6.9–9.3) .002
Total cell death, % of CD4 T cells 6.95 (4.74–10.33) 6.12 (4.14–8.93) .033
Necrosis, % of CD4 T cells 2.24 (1.34–3.50) 1.89 (1.21–3.28) .127
Apoptosis, % of CD4 T cells 3.79 (2.56–5.64) 3.32 (2.09–4.89) .041
Intrinsic apoptosis, % of CD4 T cells 2.45 (1.72–3.76) 2.08 (1.44–3.36) .038
Extrinsic apoptosis, % of CD4 T cells 2.08 (1.17–3.81) 1.59 (0.85–2.78) .033
NOTE. Data are median (interquartile range), unless otherwise indicated. HCV, hepatitis C virus; HIV, human immunodeficiency virus; VL, viral
load.
explain the failure to repopulate CD4 T cells in some HIV-
infected patients despite an adequate virologic response to
HAART [5]. Our findings support these theories and point to
intrinsic apoptosis of CD4 T cell death as the predominant
mechanism of cell destruction and the determining factor of
discordant immune response. Clinical implications that emerge
from our findings may help to answer 2 major questions about
HIV infection: when to start antiretroviral therapy and what
specific therapy to choose.
An increased rate of T lymphocyte cell death is one of the
many adverse consequences of HIV infection and amajor factor
contributing to immune deterioration [25]. Cell death can be
observed in multiple cell types, particularly in CD4 T cells, in
which apoptosis plays a determinant role [22, 26, 27]. Anti-
retroviral treatment induces a decrease in rates of apoptosis as
a result of a reduction in viral replication, which leads to de-
creased levels of viral proteins that are implicated in apopto-
sis and immune activation. This reduction contributes to the
immune recovery that is associated with HAART. However,
∼30% of patients present a discordant response to treatment,
maintaining a low CD4 T cell count despite viral suppression
[5, 8, 9]. This discordant immune response, accompanied by
the worse outcome and the faster clinical evolution observed
in these patients, has been the cause of a wide investigation
[1–7].
Although the origins of the activated phenotype and of the
increase in rates of CD4 T cell death remain unclear in dis-
cordant patients, there is enough evidence to confirm the strong
link between activation and cell death, characterized by the
high tendency of activated cells to undergo apoptosis [22].
Higher caspase-3 levels were observed in our discordant group,
thus supporting higher rates of total apoptosis in these patients.
In addition, our analysis shows that intrinsic apoptosis is the
predominant pathway of activated human CD4 T cell destruc-
tion, as reported for animal models [28], although the extrinsic
apoptotic pathway and necrosis are also involved. Interestingly,
higher rates of necrosis and intrinsic apoptosis of CD8 T cells
were also observed in discordant patients, which shows higher
activation rates in this subset. This fact reinforces the notion
that increased rates of activation are linked to higher sensitivity
to intrinsic pathways of apoptosis.
In clinical terms, the knowledge of the pathogenesis of CD4
T cell destruction is a basic step in the design of successful
strategies to improve immune reconstitution in immunological
nonresponders. The predominant implication of intrinsic ap-
optosis in poor immune recovery makes sense, because anti-
retroviral drugs may inhibit or activate apoptosis, thus influ-
encing treatment efficacy. PIs, in particular, modulate apoptosis
by preventing the opening of the mitochondrial membrane in
animal models [29, 30] and have been associated with lower
rates of CD4 T cell apoptosis in HIV-infected patients [31–34].
However, these data remain controversial [35, 36]. Surprisingly,
in our study, patients who received a PI-based regimen showed
higher apoptotic activity. This apparent paradox could be ex-
plained by the fact that these patients had a significantly worse
clinical condition (including predictors of discordant immune
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Figure 2. Predictive factors for unsatisfactory immune recovery. The ability of the indicated parameters to predict the probability of discordance
was assessed in A, univariate analysis and B, multivariate analysis, which included most of parameters from the univariate analysis. Points denote
odds ratios (ORs), and lines indicate 95% confidence intervals (CIs). ORs for nadir CD4 T cell counts were calculated for decreases of 50 cells/mL.
Asterisks denote statistical significance: * , ** . ABV, abacavir; FTC, emtricitabine; HCV, hepatitis C virus; HIV, human immunodeficiencyP ! .05 P ! .005
virus; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir; VL, viral load; 3TC, lamivudine. C, Patients were
stratified according to their recovery of CD4 T cells, measured as the difference between their current CD4 T cell count and their nadir value. Five
groups were defined by the increase in CD4 T cell count of !100 cells/mL ( ), 100–199 cells/mL ( ), 200–349 cells/mL ( ), 350–np 31 np 47 np 61
500 cells/mL ( ), and 1500 cells/mL ( ). Intrinsic apoptosis of CD4 T cells after 1 day of ex vivo culture was analyzed. Dots indicatenp 44 np 42
individual data; for illustrative purposes, discordant patients are shown as red squares and concordant patients as green circles. Median and interquartile
range are shown for each group; the P value, calculated with the Kruskal-Wallis test, applies to differences among groups.
response, such as lower nadir CD4 T cell count, longer time of
HIV infection, and higher rate of HCV coinfection) that probably
led physicians to prefer a PI-containing regimen. Multivariate
analysis, however, ruled out the use of a PI as a risk factor or as
a protective factor for a discordant response. Similarly, no as-
sociation was observed between use of abacavir-lamivudine or
tenofovir-emtricitabine and immune response. Given these re-
sults, it seems reasonable that there are no apparent differences
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between the most common antiretroviral combinations in terms
of rates of apoptosis and immune response.
Many clinical factors have been related to immune recovery
[5]. Our analysis demonstrates that low nadir CD4 T cell count
remains the strongest factor associated with a discordant im-
mune response and was firmly associated with immune acti-
vation and rates of intrinsic apoptosis. However, immune re-
sponse was not significantly related to other parameters (eg,
age, time with viral replication, or presence of HCV infection).
Particularly, HCV coinfection, whose effect on immune recov-
ery is controversial [5, 15], was not relevant in our multivariate
analysis. Therefore, our data suggest that an early initiation of
antiretroviral therapy in HIV-infected patients is a feasible in-
tervention to prevent the immune deterioration that leads to
unsatisfactory immune recovery.
In summary, our experimental data establish that CD4 T cell
hyperactivation and the intrinsic pathway of cell death represent
the determinant and final mechanisms of the unsatisfactory im-
mune recovery in discordant patients and should be targeted to
better manage treatment of these patients with more appropriate
strategies. We believe that essential clinical implications of HIV
infection could emerge from our data to help address such rel-
evant decisions as when to start antiretroviral therapy and what
specific therapy to choose. Because nadir CD4 T cell count was
the main predictive factor of immune response and because cur-
rent antiretroviral combinations had similar effects on immune
recovery, we believe that HAART should be initiated earlier and
that any common HAART combination can be used. Although
this was a large cohort, our data arise from a cross-sectional
study. Therefore, these results should be supported by further
studies designed for this purpose.
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